drugset / Trial / NCT00776438

Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines

NCT00776438

Phase 2 Completed 160 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

To further characterize the immune responses induced after an influenza vaccination performed either via the ID or the IM routes in two clearly distinct populations. Objectives: * To describe the immune response per age group and vaccine group after vaccination. * To describe the safety of the vaccines per age group and per vaccine group after vaccination.

Timeline

Start
2007-09
Primary completion
2009-02
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine 15 ug Intramuscular
Subject Influenza Virus Vaccine Vaccine 0.5 ml Intramuscular
Subject Intanza Vaccine 9 ug Intrathecal
Subject Intanza Vaccine 0.1 ml Intrathecal

Indications